Logo

ABPWW

Abpro Holdings Inc

ABPWW

Abpro Holdings Inc • NASDAQ
$0.02 ▼ -3.24% (-0.00)
Market Cap $5.30 M
52w High $0.02
52w Low $0.01
Dividend Yield 0%
P/E 0
Volume 11.39K
Outstanding Shares 296.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $2.118M ▼ $-2.984M ▲ 0% $-0.052 ▲ $-2.667M ▲
Q1-2025 $0 ▼ $2.806M ▼ $-3.887M ▲ 0% ▲ $-0.076 ▲ $-2.998M ▲
Q4-2024 $183K ▲ $8.178M ▲ $-5.509M ▼ -3.01K% ▼ $-1.92 ▼ $-5.18M ▼
Q3-2024 $0 $391.686K ▼ $-335K ▲ 0% $-0.041 ▲ $-307K ▲
Q2-2024 $0 $393.674K $-339K 0% $-0.042 $-313K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $343K ▼ $1.703M ▼ $17.298M ▼ $-16.144M ▲
Q2-2025 $2.014M ▲ $3.483M ▲ $20.43M ▼ $-17.496M ▲
Q1-2025 $1.405M ▼ $2.797M ▼ $20.608M ▲ $-18.36M ▼
Q4-2024 $2.85M ▲ $4.661M ▼ $19.607M ▲ $-15.495M ▼
Q3-2024 $13.597K $7.858M $19.541M $-11.683M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.657M ▲ $-2.281M ▼ $26K ▲ $569K ▼ $-1.686M ▼ $-2.281M ▼
Q2-2025 $-2.984M ▲ $-1.386M ▲ $0 $2.01M ▲ $624K ▲ $-1.386M ▲
Q1-2025 $-3.887M ▲ $-1.719M ▲ $0 ▲ $132K ▼ $-1.587M ▼ $-1.719M ▲
Q4-2024 $-5.509M ▼ $-8.254M ▼ $-29.639M ▼ $40.275M ▲ $2.978M ▲ $-8.254M ▼
Q3-2024 $81.325K $3.442M $29.639M $-32.673M $-188.403K $3.442M

Five-Year Company Overview

Income Statement

Income Statement Abpro is still a pre‑revenue biotech story: there is essentially no sales or gross profit yet. The income statement shows ongoing operating losses each year, reflecting research, development, and overhead costs without any offsetting product revenue. Losses appear relatively small in absolute size but are consistent, which is typical for an early clinical‑stage biotech that is investing ahead of any commercial launch. Earnings per share have been negative and drifting weaker, signaling continued dilution of value for existing shareholders as the company funds its pipeline.

Balance Sheet

Balance Sheet The balance sheet looks very thin, with a very small asset base and prior periods showing only modest cash. There is no meaningful debt reported, which reduces financial leverage risk but also suggests the company depends heavily on equity and external financings. Equity has been negative, indicating an accumulated deficit larger than the recorded assets. Overall, the balance sheet reflects a fragile financial position that leaves the company sensitive to funding conditions and execution risk.

Cash Flow

Cash Flow Cash flow is negative from operations, in line with its lack of revenue and ongoing spending on development and corporate costs. With no capital‑intensive projects, investment spending appears minimal, but free cash flow is still negative. Put simply, the company consumes cash rather than generates it and is reliant on raising capital from outside sources to keep advancing its programs.

Competitive Edge

Competitive Edge Abpro operates in a very crowded and high‑stakes part of biotech, competing with much larger, better‑funded players in oncology and eye diseases. Its edge rests on its proprietary antibody platforms and formats, which aim to make more precise, powerful, and manufacturable therapies. Partnerships with firms like Celltrion help validate the technology and extend reach, but Abpro is still a small player whose position will ultimately depend on whether its candidates show clear clinical benefits versus existing treatments and rival pipelines.

Innovation and R&D

Innovation and R&D Innovation is the core of Abpro’s story. Its DiversImmune and MultiMab platforms are designed to rapidly generate and engineer antibodies against difficult targets, and the TetraBi format aims to offer safer, more effective multi‑target antibodies. The pipeline focuses on tough cancers and serious eye diseases, with several bispecific and T‑cell–engaging antibodies moving toward early‑stage trials. However, most programs are still preclinical or just approaching the clinic, so the scientific promise is high but largely unproven in patients, and timelines to any commercial impact are long and uncertain.

Summary

Abpro is an early‑stage, pre‑revenue biotech with a highly specialized antibody platform and a focused pipeline in oncology and ophthalmology. Financially, it runs consistent losses, has a very light and strained balance sheet, and depends on external funding to operate. Strategically, its value hinges on turning its proprietary technologies and partnerships into positive clinical data over the next several years. The opportunity is tightly linked to innovation success, while risks center on scientific setbacks, trial delays, competitive pressure, and the company’s ability to maintain funding and market listing status.